ArticleTobacco induced diseases2026
The association between cigarette smoking exposure and sarcopenia assessed by Psoas Muscle Index: A secondary data analysis.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcopenia is a geriatric syndrome characterized by a progressive loss of skeletal muscle mass and strength, leading to decreased physical capacity, impaired quality of life, and increased mortality. Although smoking has multiple systemic effects, its relationship with sarcopenia remains controversial. This study aimed to investigate the relationship between varying levels of cigarette smoking exposure and sarcopenia, assessed using the Psoas Muscle Index (PMI) measured using non-contrast abdominal computed tomography (CT).
methodsThis cross-sectional analysis included 261 adult patients who underwent non-contrast abdominal CT between 2019 and 2022 at Akdeniz University Internal Medicine and Urology outpatient clinics. The patients were categorized into three groups: active smokers, passive smokers, and non-smokers. Passive smokers were defined as non-smoking individuals who reported regular exposure to secondhand cigarette smoke for at least two days per week. Individuals with conditions or medications known to affect body composition were excluded from the study. Bilateral psoas muscle cross-sectional areas at the L3 vertebral level were manually measured, and PMI was calculated (cm
resultsThere were no statistically significant differences in PMI values among active, passive, and non-smokers (p=0.138). Laboratory parameters, including C-reactive protein (CRP), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and glomerular filtration rate (GFR), were also comparable between the groups. Hemoglobin levels were significantly higher in active smokers compared to non-smokers (active: 14.40 [IQR: 13.00-15.25] vs non-smoker: 13.50 (IQR: 12.90-14.60) g/dL; p=0.029). Sarcopenia prevalence did not differ significantly among the three groups (non-smoker: 16.1%, passive smoker: 28.7%, active smoker: 16.1%; p=0.057).
conclusionsIn this cohort, neither passive nor active cigarette smoking exposure was associated with significant changes in Psoas Muscle Index or sarcopenia prevalence. Although smoking is a well-established risk factor for many diseases, its direct effect on muscle mass remains inconclusive. Further prospective studies considering smoking intensity, duration, and other confounders are warranted to clarify this relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.